KZIA ▲ +0.9% - Kazia Therapeutics Limited $KZIA KZIA KZIA - Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer Kazia Therapeutics rose 0.9% following its announcement that the first patient has been dosed in the PNOC035 clinical study evaluating paxalisib as a treatment for recurrent pediatric atypical teratoid/rhabdoid (AT/RT) brain cancer, a significant milestone in the company's clinical development program for this rare pediatric indication. 09-SEP-2026 07:33 AM ET